Sonidegib is primarily approved for the treatment of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation, or in patients who are not candidates for these treatments. Research is ongoing to explore its efficacy in other cancers, such as medulloblastoma and pancreatic cancer, which may also involve aberrant Smoothened receptor signaling.
